email print

Women should "take it personally" when it comes to breast cancer

Palm Beach symposium reveals new clues to prevention, treatment

The Breast Cancer Research Foundation's annual Palm Beach public symposium focused on risk factors, but the take home message was the value of personalized treatments. Four esteemed BCRF researchers - Judy Garber, MD, MPH, Cliff Hudis, MD, Marc Lippman, MD, and Walter Willett, MD, Dr. PH - updated attendees on everything from genetics to hormones to diet and lifestyle factors at the February 11, 2008 morning symposium held at the Flagler Museum.

"What We Know (And What We Need to Learn) About Preventing Breast Cancer"

Panel Moderator:
Clifford Hudis, MD
Chairman, BCRF Scientific Advisory Committee
Chief, Breast Cancer Medicine Service and Attending Physician
Memorial Sloan-Kettering Cancer Center, New York, NY

Panelists Introductions:
Clifford Hudis, MD

Walter C. Willett, MD, DrPH
Chair, Department of Nutrition
Professor of Epidemiology and Nutrition
Professor of Medicine
Harvard Medical School Harvard School of Public Health, Boston, MA

Judy E. Garber, MD, MPH
Member, BCRF Scientific Advisory Committee
Director, Cancer Risk & Prevention; Department of Adult Oncology
Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, MA

Marc E. Lippman, MD
Kathleen & Stanley Glaser Professor
Chairman, Department of Medicine
Miller School of Medicine, University of Miami, Miami, FL

Five-year Period for Tamoxifen / Raloxifene (Evista)
Response by:
Clifford Hudis, MD
Walter C. Willett, MD, DrPH

Discussion: Herceptin and Femara
Response by: Clifford Hudis, MD
Marc E. Lippman, MD

Distinction Between Estrogen Therapy and Aromatase Inhibitors
Response by: Clifford Hudis, MD

Does Tamoxifen Cause Leukemia?
Response by:
Marc E. Lippman, MD

Inflammatory Breast Cancer
Response by: Marc E. Lippman, MD

Lifestyle Factors Involved in Prevention
Response by:
Clifford Hudis, MD
Walter C. Willett, MD, DrPH
Judy E. Garber, MD, MPH

Reducing the Risk of Breast Cancer
Response by:
Walter C. Willett, MD, DrPH
Clifford Hudis, MD
Judy E. Garber, MD, MPH
Marc E. Lippman, MD

Predicting Breast Cancer Risk
Response by:
Walter C. Willett, MD, DrPH

Role of Raloxifene (Evista)/Tamoxifen in Reducing Breast Cancer Risk
Response by:
Marc E. Lippman, MD
Clifford Hudis, MD

Closing Statements
Clifford Hudis, MD